

1 Longitudinal Fecal Shedding of SARS-CoV-2, Pepper Mild Mottle Virus, and 2 Human Mitochondrial DNA in COVID-19 Patients

3 Pengbo Liu^{1*}, Orlando III Sablon¹, Yuke Wang¹, Stephen Patrick Hilton¹, Lana Khalil², Jessica
4 Mae Ingersoll³, Jennifer Truell³, Sri Edupuganti², Ghina Alaaeddine², Amal Naji², Eduardo
5 Monarrez², Marlene Wolfe¹, Nadine Rouphael², Colleen Kraft³, Christine L. Moe^{1*}

6 ¹Center for Global Safe Water, Sanitation, and Hygiene, Rollins School of Public Health, Emory
7 University, Atlanta, Georgia, USA

8 ²Hope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine,
9 School of Medicine, Emory University, Atlanta, Georgia, USA

10 ³Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, USA

11 *These authors share senior authorship

12

13 ABSTRACT

14 Since the coronavirus disease 2019 (COVID-19) pandemic, wastewater-based
15 epidemiology (WBE) has been widely applied in many countries and regions for
16 monitoring COVID-19 transmission in the population through testing severe acute
17 respiratory syndrome coronavirus 2 (SARS-CoV-2) in wastewater. However, the lack of
18 dynamic level of viral shedding in the wastewater and accurate number of infections in
19 the community creates challenges in predicting COVID-19 prevalence in the population
20 and interpreting WBE results. In this study, we measured SARS-CoV-2, pepper mild
21 mottle virus (PMMoV), and human mitochondrial DNA (mtDNA) in longitudinal fecal
22 samples collected from 42 COVID-19 patients for up to 42 days after diagnosis. SARS-
23 CoV-2 RNA was detected in 73.1% (19/26) of inpatient study participants in at least one
24 of the collected fecal specimens during the sampling period. Most participants shed the
25 virus within three weeks after diagnosis, but five inpatient participants still shed the virus
26 between 20 and 60 days after diagnosis. The median concentration of SARS-CoV-2 in
27 positive fecal samples was 1.08×10^5 genome copies (GC)/gram dry fecal material.
28 PMMoV and mtDNA were detected in 99.4% (154/155) and 100% (155/155) of all fecal

29 samples, respectively. The median concentrations of PMMoV RNA and mtDNA in fecal
30 samples were 1.73×10^7 and 2.49×10^8 GC/dry gram, respectively. These results provide
31 important information about the dynamics of fecal shedding of SARS-CoV-2 and two
32 human fecal indicators in COVID-19 patients. mtDNA showed higher positive rates,
33 higher concentrations, and less variability between and within individuals than PMMoV,
34 suggesting that mtDNA could be a better normalization factor for WBE results than
35 PMMoV.

36 **Key Words:** SARS-CoV-2; COVID-19; longitudinal; fecal shedding; PMMoV; mtDNA

37

38 1. INTRODUCTION

39 COVID-19 (coronavirus disease 2019) is caused by SARS-CoV-2 (severe acute
40 respiratory coronavirus 2), a positive-sense single-stranded RNA virus. Although
41 COVID-19 is a respiratory disease and patients predominantly manifest respiratory
42 symptoms, systemic and respiratory manifestations are often accompanied by
43 gastrointestinal symptoms and fecal shedding of viral RNA. Meta-analysis of studies
44 that focus on gastrointestinal (GI) infection and fecal shedding in patients with COVID-
45 19 report the prevalence of GI symptoms to be around 17.6% (1) and 28.5% (2) in
46 patients with severe COVID-19 during the acute infection phase. In COVID-19 patients,
47 the prevalence of positive RNA in stool samples was about 50% (1, 3) within the first
48 week of diagnosis. Interestingly, several studies that have collected paired longitudinal
49 respiratory and fecal samples demonstrated prolonged fecal shedding and higher viral
50 load in feces compared to the paired respiratory samples collected at the same time
51 period (3, 4). This suggests that SARS-CoV-2 infection of the GI tract persists longer

52 than in the respiratory tract and the GI tract excretes more viruses than the respiratory
53 tract. SARS-CoV-2 concentration in stool was reported to be between 10^2 to 10^7 GC/mL
54 in an early study (5) for the prototype SARS-CoV-2, but there is a lack of this
55 information for the recent variants.

56 While the presence and prevalence of SARS-CoV-2 RNA in the GI tract are well
57 established, much less is known about the duration and the amount of SARS-CoV-2
58 fecal shedding in patients with COVID-19. Natarajan et al. (3) reported that 12.7% of
59 subjects still shed SARS-CoV-2 at 4 months and 3.8% of patients shed SARS-CoV-2 at
60 7 months post diagnosis. Whereas there was no evidence of ongoing oropharyngeal
61 virus shedding at this time. Additionally, one study suggested that fecal SARS-CoV-2
62 RNA shedding may start 3-4 days before the onset of the symptoms (5), indicating that
63 the duration of SARS-CoV-2 fecal shedding may be even longer.

64 Many studies have observed significant correlations between the SARS-CoV-2 RNA
65 concentration in wastewater and the number of confirmed COVID-19 cases reported in
66 the corresponding wastewater catchment areas (6-12), which highlights the application
67 of WBE to monitor the burden of viral infection in the population. Other studies have
68 attempted to use SARS-CoV-2 fecal shedding levels as parameters in models to predict
69 the prevalence or incidence of COVID-19 in communities (8, 13, 14). Predicting
70 prevalence or incidence in the population is critical for public health decision-making.
71 This application has been explored via several statistical modeling approaches (14-16);
72 However, using modeling to accurately predict COVID-19 prevalence or incidence in
73 populations from SARS-CoV-2 concentrations in wastewater requires longitudinal and
74 quantitative SARS-CoV-2 fecal shedding data. To date, there have been several reports

75 on SARS-CoV-2 fecal shedding, but many studies lack longitudinal samples,
76 quantitative SARS-CoV-2 concentrations (report Ct values rather than absolute
77 quantification) in stool, accurate timing of when the samples were collected after the
78 onset of symptoms, specific amount of fecal material used for viral quantification, and
79 the limit of detection of the assay used for viral quantification, etc. This missing
80 information in fecal shedding data limits the appropriate application of the models and
81 the interpretation of WBE modeling results.

82 Pepper mild mottle virus (PMMoV) and human mitochondrial DNA (mtDNA) are two
83 human fecal indicators which are often analyzed along with SARS-CoV-2 quantification
84 in wastewater samples, and both are used for normalization of SARS-CoV-2
85 concentrations in wastewater. PMMoV, a plant RNA virus that causes infection in
86 pepper crops, is excreted in high concentrations in human fecal material if people
87 consume food products containing infected peppers. Up to 10^9 virion particles of
88 PMMoV have been reported per gram of human feces by dry weight (17). Because of its
89 abundance in human stool, persistence in the environment, and multiple exposure
90 pathways to humans, PMMoV is frequently reported as a human fecal indicator in WBE
91 studies (18, 19). Human mtDNA is exclusively human in origin and highly abundant in
92 human feces. However, it is less frequently reported (20, 21) than PMMoV and is
93 potentially a new, reliable human fecal indicator. This marker has been detected in high
94 copy numbers in 100% of human fecal specimens across multiple geographic regions
95 (22) and in 92% of sewage samples (23).

96 The objective of this study was to examine the fecal shedding dynamics of SARS-CoV-2
97 RNA, PMMoV, and mtDNA in longitudinal fecal samples collected from confirmed

98 COVID-19 inpatient and outpatient participants. The results can be used to better
99 predict COVID-19 prevalence or incidence in communities using mathematical modeling
100 and guide interpretation of SARS-CoV-2 RNA levels in wastewater samples using WBE
101 approaches.

102

103 **2. MATERIALS and METHODS**

104 **2.1. Study Description and Stool Sample Collection**

105 Study participants were recruited from the inpatient clinic at Emory University Hospital
106 between March 21, 2021 and September 21, 2021 and the outpatient clinic by the Hope
107 Clinic of Emory Vaccine Center between September 22, 2021 and July 28 2022. All
108 participants were required to sign an informed consent. In addition, information on
109 demographics, clinical symptoms, and COVID-19 vaccination was also collected.
110 COVID-19 patients were enrolled as study participants if an in-house real-time RT-PCR
111 test detected SARS-CoV-2 RNA in their nasopharyngeal swab samples or other
112 commercial assays (e.g., antigen test) showed SARS-CoV-2 antigen in their saliva
113 specimens within 7 days after the onset of COVID-19 symptoms. Participants with any
114 behavioral, cognitive, or psychiatric condition were excluded from the enrollment. The
115 day with SARS-CoV-2 positive detection was considered the COVID-19 confirmation
116 date in this study. The first stool sample was collected after the participant was enrolled,
117 usually within 7 days after the confirmation date. The date of the first stool sample
118 collection was defined as Day 1, and subsequent samples were collected on Days 3, 7,
119 14, 28, and 42 from the first stool sample for each subject. The sampling day was
120 converted to the day of COVID-19 confirmation for data analysis and visualization

121 purposes. Stool collection kits were provided to study participants. For inpatients, stool
122 samples were picked up from the hospital room and there was usually no delay. For
123 outpatients, stool collection kits were shipped to the home address, and study
124 participants were asked to ship samples back to the Emory study lab using prepaid
125 mailers. These samples were usually delayed for shipment and may not have been
126 kept all the way in the cold chain. Once received by the study lab, the samples were
127 immediately stored at -80°C prior to nucleic acid extraction and RT-qPCR detection.

128 **2.2. Fecal Sample Processing and Nucleic Acid Extraction.**

129 Stool samples were processed by the physical disruption method of bead lysing
130 followed by total nucleic acid extraction with an automated purification platform, Qiagen
131 EZ1 Advanced XL (Qiagen, #9001875). First, fecal specimens were thawed on ice from
132 -80°C. Each specimen was precisely weighed on an analytical balance, ranging
133 between 27.0 mg to 33.1 mg, into a 2.0 mL pre-filled 0.7 mm garnet bead tube (Omni
134 International, #19-624). Then, 600 µL of Qiagen PowerBead solution (Qiagen, #12955-
135 4-BS) was added to each wet sample. Specimens were immediately mixed on a Bead
136 Genie (Scientific Industries Inc, #SI-B100) at 3,000 rpm for 2 minutes, which introduces
137 physical agitation resulting in the lysing of the sample matrix and homogenizing the
138 sample. A 200 µL aliquot of lysate was added to 5,000 genome copies (10 µL) of
139 Bovine Respiratory Syncytial Virus (BRSV) (INFORCE 3, Zoetis, Parsippany, NJ) and
140 processed by the Qiagen EZ1 Advanced XL with the Qiagen EZ1 DSP virus kit (Qiagen,
141 # 62724) and Qiagen EZ1 Advanced DSP Virus Card (Qiagen, #9018306). BRSV
142 served as an internal processing control during the concentration and extraction
143 procedures. Total nucleic acids were extracted by a Zymo Research OneStep™ PCR

144 Inhibitor Removal kit (Zymo Research, #D6030). A Zymo-Spin™ III-HRC Column
145 (Zyme Research, #C1005) was used for each sample as per the manufacturer's
146 instructions. We inserted the column into a collection tube and added 600 µL of Prep-
147 Solution. Then, we centrifuged the column at 8,000 × g for 3 minutes. The prepared
148 column was transferred to a clean 1.5 ml microcentrifuge tube, and 60 µL of RNA was
149 added to the Zymo-Spin™ III-HRC Column. The sample was then centrifuged at 16,000
150 × g for 3 minutes. Total nucleic acid was collected and stored at 80°C. To estimate the
151 dry weight, each fecal sample was weighed, placed onto an aluminum weigh boat,
152 incubated at 105-110°C for 24 hours, and re-weighed after incubation.

153 The dry weight percent for the calculation of SARS-CoV-2 concentrations per mass of
154 dry weight was calculated using the following formula:

155 $[1 - (\text{wet mass of fecal material} - \text{dry mass of fecal material}) / \text{wet mass of fecal material}]$
156 $\times 100\%$

157 **2.3. Quantification of SARS-CoV-2, PMMoV, and mtDNA in Stool Samples using** 158 **dPCR**

159 Digital PCR was performed using the QIAcuity Digital PCR System and QIAcuity
160 OneStep Advanced Probe Kit (Qiagen, #250132) following the manufacturer's protocol.
161 The Qiagen QIAcuity instrument was programmed using the following parameters.
162 Reverse transcription was set at 50°C for 40 minutes for 1 cycle followed by PCR initial
163 heat activation at 95°C for 2 minutes. The PCR was repeated for 45 cycles at 95°C for 5
164 seconds, and at 50°C for 30 seconds. One triplex PCR was used to quantify PMMoV,
165 BRSV, and N1 (nucleocapsid gene) of SARS-CoV-2, while mtDNA was quantified in a

166 singleplex assay. For the triplex PCR assay, each 40- μ L reaction contained 10 μ L of 4 \times
167 One-step Advanced Probe Master Mix, 0.4 μ L of 100 \times OneStep RT Mix, 2 μ L of each
168 16 \times primer-probe mix of PMMoV, BRSV, and N1, 5 μ L of nucleic acid extract, and 18.6
169 μ L of RNase-free water. For the mtDNA singleplex master mix, each 40- μ L reaction
170 contained 10 μ L of 4 \times One-step Advanced Probe Master Mix, 0.4 μ L of 100 \times OneStep
171 RT Mix, 2 μ L of 16 \times primer-probe mix of mtDNA, 5 μ L of 1:100 diluted nucleic acid
172 extract, and 22.6 μ L of RNase-free water. The master mix was pipetted into a QIAGEN
173 QIAcuity 24 well 26k partition nanoplate.

174 **2.4. Data Analysis and Statistics**

175 We performed data analysis using R program (version 4.0.1). A logistic regression
176 model was used to study the association between SARS-CoV-2 positivity and other
177 variables including inpatient, outpatient, days after COVID-19 was confirmed, PMMoV,
178 and mtDNA concentration. The Pearson correlation was used to estimate the
179 association between \log_{10} -transformed PMMoV and mtDNA concentrations.

180 **3. RESULTS**

181

182 **3.1. Participant Description**

183 A total of 42 subjects with confirmed COVID-19 were enrolled in this study, and 155
184 fecal samples were collected throughout the 42-day follow-up period. Most of these
185 subjects, 61.9% (26/42), were inpatients, and 38.1% (16/42) were outpatients. Most
186 participants manifested severe clinical symptoms if hospitalized (inpatients), while
187 outpatient participants usually had mild symptoms. The self-reported COVID-19
188 vaccination status indicated that 66.7% (28/42) were vaccinated (received at least one

189 dose of COVID-19 vaccine and had a breakthrough infection) and 33.3% (14/42) were
190 unvaccinated. Among these subjects, only 14.3% (6/42) were ≥ 65 years old (Table 1).

191 **3.2. COVID-19 Clinical Symptoms**

192 To compare the clinical course of infections of vaccinated and unvaccinated
193 participants, clinical symptoms relevant to COVID-19 infection were assessed. Cough,
194 diarrhea, fever, loss of smell, and shortness of breath were more frequently observed in
195 unvaccinated subjects than in vaccinated subjects. Frequencies of headache and
196 myalgia fatigue were higher in vaccinated and in unvaccinated groups. When inpatients
197 and outpatients were compared, inpatients were much more likely to report cough,
198 diarrhea, and fever than outpatients while outpatients tended to have more symptoms of
199 headache, loss of smell, myalgia and fatigue. These differences may be caused by the
200 small number of subjects in both groups (Table 2).

201 **3.3. Longitudinal SARS-CoV-2 Fecal Shedding**

202 The SARS-CoV-2 fecal shedding patterns for each inpatient and outpatient study
203 subject are shown in Figure 1. SARS-CoV-2 RNA was detected in at least one of the
204 fecal samples collected during the sampling period for 73.1% (19/26) of inpatient
205 participants. Most SARS-CoV-2 RNA-positive samples were collected within two weeks
206 of COVID-19 diagnosis. Five inpatients still shed the virus in their stools after two
207 weeks, and one inpatient had detectable SARS-CoV-2 RNA in a stool sample at 59
208 days after COVID-19 diagnosis. For the 71 fecal samples collected from inpatients,
209 47.9% (34/71) had SARS-CoV-2 N1 gene measurements above the limit of detection of
210 our PCR assay. In contrast, outpatients showed a different fecal shedding pattern. Only
211 7.1% of 84 fecal samples collected from 16 outpatients were SARS-CoV-2 RNA
212 positive, and all of these came from four study subjects. The low proportion of SARS-

213 CoV-2 positive stool samples from outpatients may be due to delays in sample
214 collection. Interestingly, all four outpatient subjects with positive SARS-CoV-2 stool
215 samples were intermittent shedders and were excreting the virus at three or more
216 weeks after infection was confirmed.

217 **3.4. SARS-CoV-2 RNA Concentrations in Fecal Specimens**

218 Concentrations of SARS-CoV-2 RNA in stool samples ranged from 4.5×10^3 genome
219 copies (GC)/dry gram to 1.19×10^9 GC/dry gram with a median of 1.08×10^5 GC/dry gram.
220 For the 34 fecal samples from inpatients that tested positive for SARS-CoV-2 RNA, the
221 median concentration of SARS-CoV-2 RNA was 1.35×10^5 GC/dry gram. For the six
222 fecal samples from outpatient participants that tested positive for SARS-CoV-2 RNA,
223 the median concentration of SARS-CoV-2 RNA was 9.11×10^3 GC/dry gram (Figure 2,
224 bottom left). Both the SARS-CoV-2 detection rates in stool samples and the mean virus
225 RNA \log_{10} concentrations in stool were significantly different in samples from inpatients
226 versus outpatients ($p < 0.001$ and $p = 0.003$, respectively).

227 **3.5. Fecal Shedding Among Vaccinated (Breakthrough) and Unvaccinated** 228 **Participants**

229 There was little difference in the detection rates and concentrations of SARS-CoV-2
230 RNA in fecal samples from study subjects with different COVID-19 vaccination status.
231 For the 28 vaccinated participants, 53.6% (15/28) of vaccinated participants shed
232 SARS-CoV-2 in at least one of the fecal specimens collected during the study period,
233 and 26.2% (28/107) fecal samples from vaccinated participants were SARS-CoV-2 RNA
234 positive with a median concentration of 1.08×10^5 GC/dry gram. There were 14
235 participants who reported that they were unvaccinated, and 8 of them (57.1%) had
236 evidence of SARS-CoV-2 shedding in at least one of the collected fecal samples. Of the

237 48 fecal samples collected from unvaccinated participants, 25.0% (12/48) fecal samples
238 from unvaccinated participants were positive for SARS-CoV-2 RNA and the median
239 concentration was 9.14×10^4 GC/dry gram (Figure 2, bottom right).

240 **3.6. PMMoV Detection in Fecal Samples**

241 PMMoV was analyzed in each fecal sample by dPCR on the same day as the SARS-
242 CoV-2 dPCR to observe the biological variability of this fecal indicator within and
243 between individuals over the sampling period. Almost all (99.4%, 154/155) of the fecal
244 samples in this study had detectable PMMoV. The median concentration of PMMoV
245 RNA was 1.73×10^7 GC/dry gram. PMMoV RNA concentrations were highly variable over
246 the sampling period within and between the individual study subjects. Some individuals
247 showed relatively consistent concentrations of PMMoV RNA in their longitudinal
248 samples; while for others the PMMoV RNA concentrations varied across several orders
249 of magnitude among all the samples from an individual. The lowest PMMoV
250 concentration was 790 GC/dry gram, and the highest concentration was 3.51×10^9
251 GC/dry gram (Figure 3).

252 **3.7. Human mtDNA Detection in Fecal Samples**

253 Human mtDNA, another fecal indicator, was analyzed in all the collected fecal samples.
254 All 155 samples (100%) tested positive for mtDNA, and the median concentration of
255 mtDNA in all positive samples was 2.49×10^8 GC/dry gram. The concentration of mtDNA
256 ranged between 8.22×10^6 GC/dry gram and 3.88×10^{10} GC/dry gram. In contrast to
257 PMMoV, the mtDNA concentration in stool was more consistent both between and
258 within the study subjects over the study period (Figure 4).

259 **3.8. Correlation between PMMoV and mtDNA**

260 Pearson correlation analysis was performed to examine the association between
261 PMMoV and mtDNA concentrations, the two human fecal markers measured in the
262 fecal samples in this study. Figure 5 indicated a weak correlation ($p = 0.16$) between the
263 concentrations of these two markers. Interestingly, mean \log_{10} PMMoV concentration
264 was significantly higher ($p < 0.001$) in fecal specimens from outpatients compared to
265 those from inpatients.

266 267 **4. DISCUSSION**

268 In this study, we describe frequency, duration, and concentration of SARS-CoV-2,
269 PMMoV, and mtDNA shedding in fecal specimens from inpatient and outpatient study
270 subjects with COVID-19 over a 42 day period after the confirmation of SARS-CoV-2
271 infection. Consistent with other reports (24-26), study subjects who had been
272 vaccinated but had breakthrough infections were less likely to exhibit some clinical
273 symptoms, such as cough, diarrhea, fever, loss of smell, loss of taste, and shortness of
274 breath, compared to unvaccinated study subjects. Inpatient participants were more
275 likely to be shedding SARS-CoV-2 RNA in their fecal specimens and had higher
276 concentrations of the virus in their stool compared to outpatient participants. These
277 results provide important information about the dynamics of the fecal shedding of
278 SARS-CoV-2 and two human fecal indicators. Understanding the presence, magnitude,
279 and duration of these targets of interest is critical for the broad application of WBE and
280 interpretation of WBE results.

281 Although several cross-sectional studies have reported SARS-CoV-2 fecal shedding in
282 patients with COVID-19 at the early stage of infection, little is known about longitudinal
283 SARS-CoV-2 shedding. In this study, we observed that 73.1% (19/26) inpatients shed

284 SARS-CoV-2 up to three weeks and 19.2% (5/26) inpatients continued to shed viruses
285 beyond day 20; however only 25.0% (4/16) outpatients shed viruses after three weeks
286 of diagnosis. In contrast, the study led by Natarajan et al.,(3) included a total of 113
287 individuals diagnosed with COVID-19 who were followed for up to 10 months. They
288 reported that 49.2% of fecal specimens tested positive for SARS-CoV-2 during the week
289 following diagnosis using PCR-based methods, with the positivity rate declining to
290 12.7% at 4 months and 3.8% at 7 months after diagnosis. Another study reported the
291 fecal shedding results from 48 SARS-CoV-2 infected individuals and observed that
292 approximately 80% of the fecal samples collected within the first 5 days were positive
293 for SARS-CoV-2, and this positivity rate dropped to 10% at 28 days after symptom
294 onset. A median concentration of three orders GC of magnitude/mg dry weight was
295 reported in positive fecal samples (27), which is one order GC of magnitude higher
296 compared to this study.

297 Normalizing SARS-CoV-2 concentrations measured in wastewater with a human fecal
298 indicator is a common practice in order to adjust for factors that may contribute to the
299 variability in SARS-CoV-2 concentrations from distinct catchment areas and the
300 recovery of the virus from wastewater with different methods. Several fecal indicators,
301 including human ribonuclease P (37), PMMoV (38), Bacteroides HF183 (39); F-specific
302 RNA bacteriophages (40), human 18S rRNA (41), cross-assembly phage (CrAssphage)
303 (42), have been proposed. Among these recommended fecal indicators, PMMoV is
304 widely used. PMMoV is a plant RNA virus associated with pepper products and human
305 diet (17, 38). The presence and magnitude of PMMoV RNA in biological and
306 environmental samples are varied due to the geographic and dietary variations between

307 populations and individuals. These variations may complicate the application of PMMoV
308 as a normalizing indicator in some situations, such as countries with less consumption
309 of plants and pepper products. Although PMMoV has been consistently detected in
310 wastewater and has been proposed as a normalization indicator, there are few reports
311 characterizing PMMoV detection in human fecal samples. Additionally, high
312 concentrations of PMMoV have been detected in non-human fecal samples, such as
313 chickens and seagulls (43, 44), indicating that PMMoV is not human-specific and
314 detection of PMMoV in wastewater may originate from other non-human sources, eg.,
315 livestock and wildlife. Therefore, accurate characterization of the frequency of detection
316 and quantification of PMMoV in human fecal samples provides critical information for
317 better application of this marker as a normalization control in WBE. In this study,
318 PMMoV was detected in 99.4% fecal samples, with a median concentration of 1.73×10^7
319 GC/dry gram. The PMMoV concentrations measured in this study are similar to those
320 reported in one recent publication that also quantified PMMoV in human stool samples
321 using digital PCR and reported dry mass concentrations (27). In concordance with their
322 results, we observed significant variations of PMMoV concentrations between and
323 within individuals throughout the sampling period. This suggests that PMMoV levels in
324 human fecal materials may be affected by an individual's daily diet and lifestyle.

325 Human mtDNA is a human-specific intrinsic genetic marker for fecal source tracking.
326 This marker is abundant in human feces and sewage which makes it a useful indicator
327 of human fecal contamination for environmental microbial research and risk assessment
328 applications (22, 23, 45, 46). There are limited reports on the use of mtDNA as a
329 normalization control in SARS-CoV-2 wastewater studies. In this study, mtDNA was

330 detected in 100% fecal samples, with a median concentration of 2.49×10^8 GC/dry gram.

331 Our mtDNA concentrations are within the range of mtDNA concentrations in human
332 feces reported by other studies(45). Compared to PMMoV detection in human feces,
333 mtDNA was detected in all the fecal specimens, was present at ten-fold higher
334 concentrations, and exhibited little variability between and within individuals.

335 Furthermore, there are no non-human sources of this marker. These characteristics
336 suggest that mtDNA may be better suited for use as a normalization factor for WBE
337 results than PMMoV.

338 There are several limitations in this study. First, the sample size was small, with 42
339 confirmed COVID-19 patients enrolled and 155 fecal samples collected. This population
340 was not large enough to allow for stratification for further examination of the effects of
341 some demographic variables on the fecal shedding of SARS-CoV-2. Second, the
342 recruited subjects were from a limited geographic area, basically within the metro
343 Atlanta area of Georgia. Therefore, the sample may not be representative of the US
344 population, and the conclusions may not be generalizable. Third, the fecal samples
345 were collected between March 21, 2021 and July 28, 2022, when the Delta and
346 Omicron variants were prevalent. We do not know the shedding dynamics of other
347 SARS-CoV-2 variants, and the small sample size did not allow us to compare the
348 shedding dynamics of the Delta versus Omicron variants. Fourth, outpatient participants
349 had much lower proportion of SARS-CoV-2 positive fecal specimens than inpatient
350 participants in this study, and surprisingly, all the fecal samples from outpatient study
351 subjects were negative for SARS-CoV-2 within the first three weeks of COVID-19
352 diagnosis. The low SARS-CoV-2 detection rate in fecal specimens from outpatient

353 participants may be due to the delays between subject enrollment and stool sample
354 collection and possible mishandling during storage and shipment from the participants'
355 homes to the research laboratory. In contrast, fecal specimens from inpatient
356 participants were collected earlier in the course of infection and stored under optimum
357 conditions until analysis. Despite these limitations, the quantitative measurements of
358 SARS-CoV-2, PMMoV, and mtDNA in longitudinal fecal samples from confirmed
359 COVID-19 patients have significant relevance to our understanding of COVID-19
360 epidemiology, and the SARS-CoV-2 shedding information addresses a critical
361 knowledge gap for the advancement of WBE and the use of wastewater monitoring data
362 for SARS-CoV-2 to estimate COVID-19 prevalence and incidence in specific catchment
363 populations.

364 **5. ACKNOWLEDGEMENTS**

365 This study was supported by the NIH Rapid Acceleration of Diagnostics (RADx)
366 initiative (contract No. 75N92021C00012 to Ceres Nanosciences, Inc) through a
367 contract from Ceres Nanosciences to Emory University. We are grateful to Salvins J.
368 Strods, Shawn Mulvaney, Chipso Chemoyo J. Baker Afamefuna, and Jenica Patterson
369 with the NIH RADx Initiative, and Ross Dunlap, Robbie Barbero, and Ben Lepene from
370 Ceres Nanosciences, Inc.

371
372
373
374
375
376
377
378
379
380

381
382
383
384

Table 1. Demographic Characteristics of 42 Study Participants

	Yes (%)
Male	17 (40.5)
Inpatient	26 (61.9)
Vaccinated	28 (66.7)
White	24 (57.1)
Hispanic or Latin	1 (2.4)
Age (≥65 years old)	6 (14.3)

385
386
387

388 Table 2. Symptoms Among Patients Participants

Symptom	Vaccination Status		Admission Status	
	Vaccinated (N=28) %	Unvaccinated (N=14) %	Inpatient (N=26) %	Outpatient (N=16) %
Cough	35.7	71.4	61.9	18.8
Diarrhea	7.1	28.6	14.3	6.2
Fever	28.6	42.9	47.6	12.5
Headache	35.7	21.4	19.0	43.8
Loss of smell	17.9	21.4	19.0	31.2
Loss of taste	14.3	14.3	19.0	25.0
Myalgia/fatigue	60.7	50.0	47.6	75.0
Shortness of Breath	46.4	57.1	52.4	50.0
Other symptoms	21.4	0	23.8	18.8
ICU* stay	4.0	0	4.8	0

389 *Intensive care unit
390

391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421

422

423

424

425

426
427
428

Figure 1. SARS-CoV-2 RNA longitudinal shedding dynamics in stool samples of COVID-19 patients in this study. The patient IDs are shown on the y-axis. The x-axis indicates days after COVID-19 diagnosis was confirmed. Patients 001–031 were enrolled as inpatients, and patients 035–074 were enrolled as outpatients. Three patients with unclear confirmation dates were excluded from this figure. Red circles indicate positive SARS-CoV-2 detection, and blue circles indicate the sample was negative for SARS-CoV-2 RNA by dPCR.

Figure 2. Boxplot of \log_{10} -transformed SARS-CoV-2 RNA concentrations (genome copies/dry gram, y-axis) in 155 fecal samples from inpatients vs. outpatients, based on status when enrolled, (bottom left, x-axis) and 146 fecal samples from vaccinated vs. unvaccinated study subjects (bottom right, x-axis). The horizontal lines in boxes denote the 50th percentiles of SARS-CoV-2 RNA concentrations. The top boxes represent the fraction of SARS-CoV-2 RNA positive samples in each group.

Figure 3. Boxplot of \log_{10} -transformed PMMoV concentration (genome copies/dry gram) in inpatient (top) and outpatient (bottom) study subjects. Each box summarizes the range of PMMoV concentrations in multiple fecal samples from an individual, and the vertical line in the box represents the median PMMoV concentration. The vertical line without the box indicates only one sample was tested for PMMoV for that individual.

429 Figure 4. Boxplot of \log_{10} -transformed mtDNA concentration (GC/dry gram) in inpatient (top) and
430 outpatient (bottom) study subjects. Each box summarizes the range of mtDNA concentrations in
431 multiple fecal samples from an individual, and the vertical line in the box represents the median
432 mtDNA concentration. The vertical line without the box indicates only one sample was tested for
433 mtDNA for that individual.
434

435

436
437 Figure 5. Pearson correlation between \log_{10} -transformed PMMoV RNA and mtDNA
438 concentrations (GC/dry gram) from fecal samples of inpatients (green) and outpatients (red) in
439 this study.

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460 References

- 461 1. Cheung KS, Hung IFN, Chan PPY, Lung KC, Tso E, Liu R, Ng YY, Chu MY, Chung
462 TWH, Tam AR, Yip CCY, Leung KH, Fung AY, Zhang RR, Lin Y, Cheng HM, Zhang
463 AJX, To KKW, Chan KH, Yuen KY, Leung WK. 2020. Gastrointestinal Manifestations of
464 SARS-CoV-2 Infection and Virus Load in Fecal Samples From a Hong Kong Cohort:
465 Systematic Review and Meta-analysis. *Gastroenterology* 159:81-95.
- 466 2. Zhou JQ, Liu GX, Huang XL, Gan HT. 2022. The importance of fecal nucleic acid
467 detection in patients with coronavirus disease (COVID-19): A systematic review and
468 meta-analysis. *J Med Virol* 94:2317-2330.
- 469 3. Natarajan A, Zlitni S, Brooks EF, Vance SE, Dahlen A, Hedlin H, Park RM, Han A,
470 Schmidtke DT, Verma R, Jacobson KB, Parsonnet J, Bonilla HF, Singh U, Pinsky BA,
471 Andrews JR, Jagannathan P, Bhatt AS. 2022. Gastrointestinal symptoms and fecal
472 shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection. *Med* 3:371-
473 387 e9.
- 474 4. Yuan C, Wang H, Li K, Tang A, Dai Y, Wu B, Zhang H, Chen J, Liu J, Wu W, Gu S,
475 Wang H, Xu H, Wu M, Yu M, Wang Y, Yu X, He J, Liu S, Zhang Y, Tong Z, Yan J. 2021.
476 SARS-CoV-2 viral shedding characteristics and potential evidence for the priority for
477 faecal specimen testing in diagnosis. *PLoS One* 16:e0247367.
- 478 5. Jones DL, Baluja MQ, Graham DW, Corbishley A, McDonald JE, Malham SK, Hillary LS,
479 Connor TR, Gaze WH, Moura IB, Wilcox MH, Farkas K. 2020. Shedding of SARS-CoV-2
480 in feces and urine and its potential role in person-to-person transmission and the
481 environment-based spread of COVID-19. *Sci Total Environ* 749:141364.
- 482 6. Nemudryi A, Nemudraia A, Wiegand T, Surya K, Buyukyoruk M, Cicha C, Vanderwood
483 KK, Wilkinson R, Wiedenheft B. 2020. Temporal Detection and Phylogenetic
484 Assessment of SARS-CoV-2 in Municipal Wastewater. *Cell Rep Med* 1:100098.
- 485 7. Roka E, Khayer B, Kis Z, Kovacs LB, Schuler E, Magyar N, Malnasi T, Oravecz O, Palyi
486 B, Pandics T, Vargha M. 2021. Ahead of the second wave: Early warning for COVID-19
487 by wastewater surveillance in Hungary. *Sci Total Environ* 786:147398.
- 488 8. Li X, Zhang S, Sherchan S, Orive G, Lertxundi U, Haramoto E, Honda R, Kumar M,
489 Arora S, Kitajima M, Jiang G. 2023. Correlation between SARS-CoV-2 RNA
490 concentration in wastewater and COVID-19 cases in community: A systematic review
491 and meta-analysis. *J Hazard Mater* 441:129848.
- 492 9. Lu E, Ai Y, Davis A, Straathof J, Halloran K, Hull N, Winston R, Weir MH, Soller J,
493 Bohrerova Z, Oglesbee M, Lee J. 2022. Wastewater surveillance of SARS-CoV-2 in
494 dormitories as a part of comprehensive university campus COVID-19 monitoring.
495 *Environ Res* 212:113580.
- 496 10. Brooks YM, Gryskwicz B, Sidaway E, Shelley B, Coroi L, Downing M, Downing T,
497 McDonnell S, Ostrye D, Hoop K, Parrish G. 2023. A case study of a community-
498 organized wastewater surveillance in a small community: correlating weekly reported
499 COVID-19 cases with SARS-CoV-2 RNA concentrations during fall 2020 to summer
500 2021 in Yarmouth, ME. *J Water Health* 21:329-342.
- 501 11. Acosta N, Bautista MA, Hollman J, McC Calder J, Beaudet AB, Man L, Waddell BJ, Chen
502 J, Li C, Kuzma D, Bhatnagar S, Leal J, Meddings J, Hu J, Cabaj JL, Ruecker NJ,
503 Naugler C, Pillai DR, Achari G, Ryan MC, Conly JM, Frankowski K, Hubert CR, Parkins
504 MD. 2021. A multicenter study investigating SARS-CoV-2 in tertiary-care hospital
505 wastewater. viral burden correlates with increasing hospitalized cases as well as
506 hospital-associated transmissions and outbreaks. *Water Res* 201:117369.
- 507 12. Ai Y, Davis A, Jones D, Lemeshow S, Tu H, He F, Ru P, Pan X, Bohrerova Z, Lee J.
508 2021. Wastewater SARS-CoV-2 monitoring as a community-level COVID-19 trend
509 tracker and variants in Ohio, United States. *Sci Total Environ* 801:149757.

- 510 13. McMahan CS, Lewis D, Deaver JA, Dean D, Rennert L, Kalbaugh CA, Shi L, Kriebel D,
511 Graves D, Popat SC, Karanfil T, Freedman DL. 2022. Predicting COVID-19 Infected
512 Individuals in a Defined Population from Wastewater RNA Data. *ACS ES T Water*
513 2:2225-2232.
- 514 14. Joseph-Duran B, Serra-Compte A, Sarrias M, Gonzalez S, Lopez D, Prats C, Catala M,
515 Alvarez-Lacalle E, Alonso S, Arnaldos M. 2022. Assessing wastewater-based
516 epidemiology for the prediction of SARS-CoV-2 incidence in Catalonia. *Sci Rep*
517 12:15073.
- 518 15. McMahan CS, Self S, Rennert L, Kalbaugh C, Kriebel D, Graves D, Colby C, Deaver JA,
519 Popat SC, Karanfil T, Freedman DL. 2021. COVID-19 wastewater epidemiology: a
520 model to estimate infected populations. *Lancet Planet Health* 5:e874-e881.
- 521 16. Proverbio D, Kemp F, Magni S, Ogorzaly L, Cauchie HM, Goncalves J, Skupin A, Aalto
522 A. 2022. Model-based assessment of COVID-19 epidemic dynamics by wastewater
523 analysis. *Sci Total Environ* 827:154235.
- 524 17. Zhang T, Breitbart M, Lee WH, Run JQ, Wei CL, Soh SW, Hibberd ML, Liu ET, Rohwer
525 F, Ruan Y. 2006. RNA viral community in human feces: prevalence of plant pathogenic
526 viruses. *PLoS Biol* 4:e3.
- 527 18. Maal-Bared R, Qiu Y, Li Q, Gao T, Hrudey SE, Bhavanam S, Ruecker NJ, Ellehoj E, Lee
528 BE, Pang X. 2023. Does normalization of SARS-CoV-2 concentrations by Pepper Mild
529 Mottle Virus improve correlations and lead time between wastewater surveillance and
530 clinical data in Alberta (Canada): comparing twelve SARS-CoV-2 normalization
531 approaches. *Sci Total Environ* 856:158964.
- 532 19. Ahmed W, Bivins A, Payyappat S, Cassidy M, Harrison N, Besley C. 2022. Distribution
533 of human fecal marker genes and their association with pathogenic viruses in untreated
534 wastewater determined using quantitative PCR. *Water Res* 226:119093.
- 535 20. Hajj-Mohamad M, Hachad M, Deschamps G, Sauve S, Villemur R, Blais MA, Prevost M,
536 Dorner S. 2019. Fecal contamination of storm sewers: Evaluating wastewater
537 micropollutants, human-specific *Bacteroides* 16S rRNA, and mitochondrial DNA genetic
538 markers as alternative indicators of sewer cross connections. *Sci Total Environ* 659:548-
539 560.
- 540 21. Ragot R, Villemur R. 2022. Influence of temperature and water quality on the
541 persistence of human mitochondrial DNA, human Hf183 *Bacteroidales*, fecal coliforms
542 and enterococci in surface water in human fecal source tracking context. *Sci Total*
543 *Environ* 838:156025.
- 544 22. Zhu K, Suttner B, Pickering A, Konstantinidis KT, Brown J. 2020. A novel droplet digital
545 PCR human mtDNA assay for fecal source tracking. *Water Res* 183:116085.
- 546 23. Tanvir Pasha ABM, Hinojosa J, Phan D, Lopez A, Kapoor V. 2020. Detection of human
547 fecal pollution in environmental waters using human mitochondrial DNA and correlation
548 with general and human-associated fecal genetic markers. *J Water Health* 18:8-18.
- 549 24. Bajpai J, Kant S, Verma A, Patwa AK, Atam V, Chaudhary SC, Pandey A. 2022. The
550 Severity of COVID 19 Pneumonia in Vaccinated vs. Non-vaccinated Patients in the
551 Second Wave: An Experience From a Tertiary Care Center in India. *Cureus* 14:e25378.
- 552 25. Nakakubo S, Kishida N, Okuda K, Kamada K, Iwama M, Suzuki M, Yokota I, Ito YM,
553 Nasuhara Y, Boucher RC, Konno S. 2023. Associations of COVID-19 symptoms with
554 omicron subvariants BA.2 and BA.5, host status, and clinical outcomes in Japan: a
555 registry-based observational study. *Lancet Infect Dis* 23:1244-1256.
- 556 26. Tian W, Ren X, Han M, Zhang Y, Gao X, Chen Z, Zhang W. 2022. Epidemiological and
557 clinical characteristics of vaccinated COVID-19 patients: A meta-analysis and systematic
558 review. *Int J Immunopathol Pharmacol* 36:3946320221141802.
- 559 27. Arts PJ, Kelly JD, Midgley CM, Anglin K, Lu S, Abedi GR, Andino R, Bakker KM,
560 Banman B, Boehm AB, Briggs-Hagen M, Brouwer AF, Davidson MC, Eisenberg MC,

- 561 Garcia-Knight M, Knight S, Peluso MJ, Pineda-Ramirez J, Diaz Sanchez R, Saydah S,
562 Tassetto M, Martin JN, Wigginton KR. 2023. Longitudinal and quantitative fecal shedding
563 dynamics of SARS-CoV-2, pepper mild mottle virus, and crAssphage. *mSphere*
564 8:e0013223.
- 565 28. Xiao F, Sun J, Xu Y, Li F, Huang X, Li H, Zhao J, Huang J, Zhao J. 2020. Infectious
566 SARS-CoV-2 in Feces of Patient with Severe COVID-19. *Emerg Infect Dis* 26:1920-
567 1922.
- 568 29. Jeong HW, Kim SM, Kim HS, Kim YI, Kim JH, Cho JY, Kim SH, Kang H, Kim SG, Park
569 SJ, Kim EH, Choi YK. 2020. Viable SARS-CoV-2 in various specimens from COVID-19
570 patients. *Clin Microbiol Infect* 26:1520-1524.
- 571 30. Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, Tan W. 2020. Detection of SARS-CoV-2 in
572 Different Types of Clinical Specimens. *JAMA* 323:1843-1844.
- 573 31. Zhang YN, Zhang QY, Li XD, Xiong J, Xiao SQ, Wang Z, Zhang ZR, Deng CL, Yang XL,
574 Wei HP, Yuan ZM, Ye HQ, Zhang B. 2020. Gemcitabine, lycorine and oxysophoridine
575 inhibit novel coronavirus (SARS-CoV-2) in cell culture. *Emerg Microbes Infect* 9:1170-
576 1173.
- 577 32. Wolfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Muller MA, Niemeyer D,
578 Jones TC, Vollmar P, Rothe C, Hoelscher M, Bleicker T, Brunink S, Schneider J,
579 Ehmann R, Zwirgmaier K, Drosten C, Wendtner C. 2020. Virological assessment of
580 hospitalized patients with COVID-2019. *Nature* 581:465-469.
- 581 33. Albert S, Ruiz A, Peman J, Salavert M, Domingo-Calap P. 2021. Lack of evidence for
582 infectious SARS-CoV-2 in feces and sewage. *Eur J Clin Microbiol Infect Dis* 40:2665-
583 2667.
- 584 34. Britton GJ, Chen-Liaw A, Cossarini F, Livanos AE, Spindler MP, Plitt T, Eggers J, Mogno
585 I, Gonzalez-Reiche AS, Siu S, Tankelevich M, Grinspan LT, Dixon RE, Jha D, van de
586 Guchte A, Khan Z, Martinez-Delgado G, Amanat F, Hoagland DA, tenOever BR,
587 Dubinsky MC, Merad M, van Bakel H, Krammer F, Bongers G, Mehandru S, Faith JJ.
588 2021. Limited intestinal inflammation despite diarrhea, fecal viral RNA and SARS-CoV-2-
589 specific IgA in patients with acute COVID-19. *Sci Rep* 11:13308.
- 590 35. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, Schiergens
591 TS, Herrler G, Wu NH, Nitsche A, Muller MA, Drosten C, Pohlmann S. 2020. SARS-
592 CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically
593 Proven Protease Inhibitor. *Cell* 181:271-280 e8.
- 594 36. Maffia-Bizzozero S, Cevallos C, Lenicov FR, Freiburger RN, Lopez CAM, Guano
595 Toaquiza A, Sviercz F, Jarmoluk P, Bustos C, D'Addario AC, Quarleri J, Delpino MV.
596 2023. Viable SARS-CoV-2 Omicron sub-variants isolated from autopsy tissues. *Front*
597 *Microbiol* 14:1192832.
- 598 37. Holm RH, Nagarkar M, Yeager RA, Talley D, Chaney AC, Rai JP, Mukherjee A, Rai SN,
599 Bhatnagar A, Smith T. 2022. Surveillance of RNase P, PMMoV, and CrAssphage in
600 wastewater as indicators of human fecal concentration across urban sewer
601 neighborhoods, Kentucky. *FEMS Microbes* 3:1-12.
- 602 38. Hamza H, Rizk NM, Gad MA, Hamza IA. 2019. Pepper mild mottle virus in wastewater in
603 Egypt: a potential indicator of wastewater pollution and the efficiency of the treatment
604 process. *Arch Virol* 164:2707-2713.
- 605 39. Chettleburgh C, Ma SX, Swinwood-Sky M, McDougall H, Kireina D, Taggar G, McBean
606 E, Parreira V, Goodridge L, Habash M. 2023. Evaluation of four human-associated fecal
607 biomarkers in wastewater in Southern Ontario. *Sci Total Environ* 904:166542.
- 608 40. He Z, Dong L, Zhu P, Zhang Z, Xu T, Zhang D, Pan X. 2022. Nano-scale analysis of
609 uranium release behavior from river sediment in the Ili basin. *Water Res* 227:119321.
- 610 41. Greenwald HD, Kennedy LC, Hinkle A, Whitney ON, Fan VB, Crits-Christoph A, Harris-
611 Lovett S, Flamholz AI, Al-Shayeb B, Liao LD, Beyers M, Brown D, Chakrabarti AR, Dow

- 612 J, Frost D, Koekemoer M, Lynch C, Sarkar P, White E, Kantor R, Nelson KL. 2021.
613 Tools for interpretation of wastewater SARS-CoV-2 temporal and spatial trends
614 demonstrated with data collected in the San Francisco Bay Area. *Water Res X*
615 12:100111.
- 616 42. Crank K, Li X, North D, Ferraro GB, Iaconelli M, Mancini P, La Rosa G, Bibby K. 2020.
617 CrAssphage abundance and correlation with molecular viral markers in Italian
618 wastewater. *Water Res* 184:116161.
- 619 43. Malla B, Makise K, Nakaya K, Mochizuki T, Yamada T, Haramoto E. 2019. Evaluation of
620 Human- and Animal-Specific Viral Markers and Application of CrAssphage, Pepper Mild
621 Mottle Virus, and Tobacco Mosaic Virus as Potential Fecal Pollution Markers to River
622 Water in Japan. *Food Environ Virol* 11:446-452.
- 623 44. Rosario K, Symonds EM, Sinigalliano C, Stewart J, Breitbart M. 2009. Pepper mild
624 mottle virus as an indicator of fecal pollution. *Appl Environ Microbiol* 75:7261-7.
- 625 45. Zhu KJ, Suttner B, Knee J, Capone D, Moe CL, Stauber CE, Konstantinidis KT, Wallach
626 TE, Pickering AJ, Brown J. 2022. Elevated Fecal Mitochondrial DNA from Symptomatic
627 Norovirus Infections Suggests Potential Health Relevance of Human Mitochondrial DNA
628 in Fecal Source Tracking. *Environ Sci Technol Lett* 9:543-550.
- 629 46. He X, Liu P, Zheng G, Chen H, Shi W, Cui Y, Ren H, Zhang XX. 2016. Evaluation of five
630 microbial and four mitochondrial DNA markers for tracking human and pig fecal pollution
631 in freshwater. *Sci Rep* 6:35311.

632









